BACKGROUND: We investigated retrospectively the operative outcomes of portal vein resection (PVR) for portal vein (PV) and/or superior mesenteric vein (SMV) involvement and clarified the validity of PVR. METHODS: Between 1993 and 2006, 84 patients with invasive pancreatic head adenocarcinoma were resected by pancreatoduodenectomy with macroscopically curative resection. Forty-two patients underwent PVR by means of segmental resection with end-to-end anastomosis in 27 patients and autologous vein graft using an external iliac vein in 15 patients because of macroscopic venous involvement. Venous involvement was classified macroscopically as unilateral involvement (< or =180 degrees ; n = 27) or circumferential involvement (n = 15) and as short (the length of PVR < 3 cm; n = 15) or long (> or =3 cm; n = 27). Histopathologic parameters and survival were analyzed to confirm prognostic factors. RESULTS: Morbidity and mortality were not different based on PVR status. Median and 5-year survivals were 26 months and 32%, respectively, when there was no PVR (n = 42) and 12 months and 17% when there was PVR (n = 42); these values of median and 5-year survivals differed (P < .04 each) between the groups without and with PVR. Limiting the analysis to R0 (histologically curative) resections, median and 5-year survivals were 26 months and 34% when there was no PVR (n = 39) and 20 months and 23% when there was PVR (n = 32); these survivals were not significantly different between groups. In patients with PVR, there were no statistical differences in survival between those resected with or without a venous allograft and those with unilateral or circumferential involvement; however, short PVR showed better 5-year survival than long PVR (39% vs 4%; P = .017) despite similar positive rates of histologic venous invasion. CONCLUSION: PVR has comparable survival compared with no PVR only in patients undergoing an R0 resection. The short PV/SMV invasion that requires PVR <3 cm in length can result in respectable survival rates.
BACKGROUND: We investigated retrospectively the operative outcomes of portal vein resection (PVR) for portal vein (PV) and/or superior mesenteric vein (SMV) involvement and clarified the validity of PVR. METHODS: Between 1993 and 2006, 84 patients with invasive pancreatic head adenocarcinoma were resected by pancreatoduodenectomy with macroscopically curative resection. Forty-two patients underwent PVR by means of segmental resection with end-to-end anastomosis in 27 patients and autologous vein graft using an external iliac vein in 15 patients because of macroscopic venous involvement. Venous involvement was classified macroscopically as unilateral involvement (< or =180 degrees ; n = 27) or circumferential involvement (n = 15) and as short (the length of PVR < 3 cm; n = 15) or long (> or =3 cm; n = 27). Histopathologic parameters and survival were analyzed to confirm prognostic factors. RESULTS: Morbidity and mortality were not different based on PVR status. Median and 5-year survivals were 26 months and 32%, respectively, when there was no PVR (n = 42) and 12 months and 17% when there was PVR (n = 42); these values of median and 5-year survivals differed (P < .04 each) between the groups without and with PVR. Limiting the analysis to R0 (histologically curative) resections, median and 5-year survivals were 26 months and 34% when there was no PVR (n = 39) and 20 months and 23% when there was PVR (n = 32); these survivals were not significantly different between groups. In patients with PVR, there were no statistical differences in survival between those resected with or without a venous allograft and those with unilateral or circumferential involvement; however, short PVR showed better 5-year survival than long PVR (39% vs 4%; P = .017) despite similar positive rates of histologic venous invasion. CONCLUSION: PVR has comparable survival compared with no PVR only in patients undergoing an R0 resection. The short PV/SMV invasion that requires PVR <3 cm in length can result in respectable survival rates.
Authors: Marc W Fromer; Jenci Hawthorne; Prejesh Philips; Michael E Egger; Charles R Scoggins; Kelly M McMasters; Robert C G Martin Journal: Ann Surg Oncol Date: 2021-06-04 Impact factor: 5.344
Authors: Manju D Chandrasegaram; Guy D Eslick; Wayne Lee; Mark E Brooke-Smith; Rob Padbury; Christopher S Worthley; John W Chen; John A Windsor Journal: HPB (Oxford) Date: 2013-12-18 Impact factor: 3.647